硝苯地平缓释片Ⅰ、Ⅱ和Ⅲ有怎么区别?别吃错了!(附联合用药方案)

2018-04-26 佚名 店讯通

最早应用于临床治疗高血压的硝苯地平是普通片,后来研究发现,硝苯地平片虽然起效快,但由于其半衰期短,需要一日服药多次,不能24小时平稳降压,心血管疾病的风险并未显着降低。

硝苯地平,它是治疗高血压、心绞痛的常用药之一。

但是很多高血压的患者对于硝苯地平能不能长期吃,缓释片Ⅰ、Ⅱ和Ⅲ有什么区别等比较关心,今天,就给大家详细讲解下它们的区别和联合用药。

最早应用于临床治疗高血压的硝苯地平是普通片,后来研究发现,硝苯地平片虽然起效快,但由于其半衰期短,需要一日服药多次,不能24小时平稳降压,心血管疾病的风险并未显着降低。

随着药剂学的不断发展,一些生产企业开发出能够使硝苯地平缓慢释放的缓释剂型。与普通制剂相比, 具有治疗作用持久、毒副作用低、用药次数少的特点。但即使都是硝苯地平缓释片(Ⅰ)、(Ⅱ)、(Ⅲ)三种也各不相同。

1.苯地平缓释片Ⅰ、Ⅱ和Ⅲ的区别

1)用法用量不同

硝苯地平缓释片Ⅰ和Ⅱ从药品规格上来区分。硝苯地平缓释片Ⅰ的规格为10mg;硝苯地平缓释片Ⅱ的规格为20mg;硝苯地平缓释片Ⅲ的规格为30mg。

2)作用时间不同

硝苯地平缓释片(Ⅰ)、(Ⅱ)服用一次能够维持最低血药浓度12小时左右,而硝苯地平缓释片(Ⅲ)能够24小时近似恒速释放硝苯地平,类似于控释片。

3)服用时间不同

硝苯地平缓释片(Ⅰ)、(Ⅱ)一般空腹服用。硝苯地平缓释片(Ⅲ)虽然说明书也是建议空腹情况下用水整片吞服。但由于其不受胃肠道蠕动及PH值影响,服药时间不受就餐时间的限制。

4)能否掰开服用

为了避免破坏药物缓释结构,发挥作用持久疗效,缓释剂型一般不能嚼碎服用。但临床有时需要减少药物剂量,这三种缓释剂型中(Ⅰ)、(Ⅲ)不能掰开服用;但(Ⅱ)有的产品能够沿片面“中心线”完整分开半片服用。

5)工艺不同

硝苯地平缓释片Ⅰ和Ⅱ从生产工艺上来区分。硝苯地平缓释片Ⅱ是按照控释片的制造工艺来生产的。

2.联合用药

硝苯地平缓释片+鱼油+卵磷脂+钙镁片

硝苯地平缓释片

硝苯地平对轻、中、重度高血压均有降压作用。目前多推荐使用缓释片剂,以减轻迅速降压造成的反射性交感性活性增加。

鱼油

鱼油的主要成分为EPA和DHA。EPA可降血脂,预防动脉粥样硬化,保护心脑血管,降血压;DHA俗称“脑黄金”,是人类脑部必需的脂肪酸,能延缓大脑衰老,增强记忆力,预防老年痴呆。

卵磷脂

卵磷脂是血管“清道夫”,具有乳化、分解油脂的作用,清除过氧化物,使血液中胆固醇及中性脂肪含量降低,减少脂肪在血管内壁的滞留时间,促进粥样硬化的消散,促进血液循环,辅助降血压。

钙镁片

钙镁同补,有助于控制高血压,并能降低动脉粥样硬化发生的风险。

3.注意事项

1)硝苯地平缓释片,除另有规定外,除了Ⅱ有的产品可以掰开,一般应整片用水送服,严禁爵碎或击碎分次服用。

2)硝苯地平不应与西柚同时服用,因为西柚能减慢硝苯地平的体内代谢速度,从而加强硝苯地平的作用。

3)中止服用钙拮抗剂时应逐渐减量,没有医生指示,不要中止服药。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1801311, encodeId=8285180131132, content=<a href='/topic/show?id=0bb7e35362c' target=_blank style='color:#2F92EE;'>#硝苯地#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73536, encryptionId=0bb7e35362c, topicName=硝苯地)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jan 13 20:41:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455856, encodeId=b6a11455856c0, content=<a href='/topic/show?id=61e3e3537e9' target=_blank style='color:#2F92EE;'>#硝苯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73537, encryptionId=61e3e3537e9, topicName=硝苯地平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2aa55745904, createdName=smlt2010, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514283, encodeId=c93b1514283d5, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309841, encodeId=2b4a30984136, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:43 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309640, encodeId=b30430964079, content=非常实用 非常感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Fri Apr 27 05:46:02 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309622, encodeId=e174309622c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Apr 27 04:57:26 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1801311, encodeId=8285180131132, content=<a href='/topic/show?id=0bb7e35362c' target=_blank style='color:#2F92EE;'>#硝苯地#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73536, encryptionId=0bb7e35362c, topicName=硝苯地)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jan 13 20:41:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455856, encodeId=b6a11455856c0, content=<a href='/topic/show?id=61e3e3537e9' target=_blank style='color:#2F92EE;'>#硝苯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73537, encryptionId=61e3e3537e9, topicName=硝苯地平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2aa55745904, createdName=smlt2010, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514283, encodeId=c93b1514283d5, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309841, encodeId=2b4a30984136, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:43 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309640, encodeId=b30430964079, content=非常实用 非常感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Fri Apr 27 05:46:02 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309622, encodeId=e174309622c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Apr 27 04:57:26 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1801311, encodeId=8285180131132, content=<a href='/topic/show?id=0bb7e35362c' target=_blank style='color:#2F92EE;'>#硝苯地#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73536, encryptionId=0bb7e35362c, topicName=硝苯地)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jan 13 20:41:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455856, encodeId=b6a11455856c0, content=<a href='/topic/show?id=61e3e3537e9' target=_blank style='color:#2F92EE;'>#硝苯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73537, encryptionId=61e3e3537e9, topicName=硝苯地平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2aa55745904, createdName=smlt2010, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514283, encodeId=c93b1514283d5, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309841, encodeId=2b4a30984136, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:43 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309640, encodeId=b30430964079, content=非常实用 非常感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Fri Apr 27 05:46:02 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309622, encodeId=e174309622c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Apr 27 04:57:26 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1801311, encodeId=8285180131132, content=<a href='/topic/show?id=0bb7e35362c' target=_blank style='color:#2F92EE;'>#硝苯地#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73536, encryptionId=0bb7e35362c, topicName=硝苯地)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jan 13 20:41:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455856, encodeId=b6a11455856c0, content=<a href='/topic/show?id=61e3e3537e9' target=_blank style='color:#2F92EE;'>#硝苯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73537, encryptionId=61e3e3537e9, topicName=硝苯地平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2aa55745904, createdName=smlt2010, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514283, encodeId=c93b1514283d5, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309841, encodeId=2b4a30984136, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:43 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309640, encodeId=b30430964079, content=非常实用 非常感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Fri Apr 27 05:46:02 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309622, encodeId=e174309622c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Apr 27 04:57:26 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-04-27 yfjms

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1801311, encodeId=8285180131132, content=<a href='/topic/show?id=0bb7e35362c' target=_blank style='color:#2F92EE;'>#硝苯地#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73536, encryptionId=0bb7e35362c, topicName=硝苯地)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jan 13 20:41:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455856, encodeId=b6a11455856c0, content=<a href='/topic/show?id=61e3e3537e9' target=_blank style='color:#2F92EE;'>#硝苯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73537, encryptionId=61e3e3537e9, topicName=硝苯地平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2aa55745904, createdName=smlt2010, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514283, encodeId=c93b1514283d5, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309841, encodeId=2b4a30984136, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:43 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309640, encodeId=b30430964079, content=非常实用 非常感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Fri Apr 27 05:46:02 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309622, encodeId=e174309622c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Apr 27 04:57:26 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-04-27 871538379

    非常实用 非常感谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1801311, encodeId=8285180131132, content=<a href='/topic/show?id=0bb7e35362c' target=_blank style='color:#2F92EE;'>#硝苯地#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73536, encryptionId=0bb7e35362c, topicName=硝苯地)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jan 13 20:41:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455856, encodeId=b6a11455856c0, content=<a href='/topic/show?id=61e3e3537e9' target=_blank style='color:#2F92EE;'>#硝苯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73537, encryptionId=61e3e3537e9, topicName=硝苯地平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2aa55745904, createdName=smlt2010, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514283, encodeId=c93b1514283d5, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 28 13:41:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309841, encodeId=2b4a30984136, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:43 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309640, encodeId=b30430964079, content=非常实用 非常感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35e76003, createdName=871538379, createdTime=Fri Apr 27 05:46:02 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309622, encodeId=e174309622c9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Apr 27 04:57:26 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-04-27 青山颖钰

    学习了

    0

相关资讯

一文看懂氨氯地平片与硝苯地平控释片的区别

氨氯地平片和硝苯地平控释片,是临床常用的钙拮抗剂类药物。两种药物均属长效制剂,每天给药一次,既减小了血压的波动,又提高了患者对治疗的依从性,从而降低心血管事件及靶器官损伤的风险。

服用硝苯地平控释片,能不能喝点红酒?

硝苯地平普通片,因有过度降压和加快心率作用,可增加心绞痛死亡率,已很少使用。硝苯地平控释片,是一种渗透泵新制剂,可使药物恒定释放16~18小时,每天服一次,是治疗高血压和冠心病的常用药。

别再舌下含服硝苯地平!高血压亚急症这样处理

高血压危象指的是短期内血压急剧升高,达到收缩压≥180 mmHg或舒张压≥110 mmHg,或者收缩压<180 mmHg且舒张压<110 mmHg但已远高于患者正常血压的情况。为了指导治疗,高血压危象可以分为两种:高血压急症和高血压亚急症。

降压:可以舌下含服硝苯地平控释片吗?

这个问题的回答是否定的,不宜舌下含服硝苯地平控释片用于快速降压。

吞了两百片硝苯地平的姑娘,后来怎样了?

也许是现在的生活压力越来越大了,总有那么些人,一时浑噩下,轻易选择终结自己的生命。开导劝解我们不一定能做好,但对有幸及时来医院就诊的患者,专业的救治知识确是我们必须具备的。

Hypertension:孕期伴慢性高血压女性降压:拉贝洛尔还是硝苯地平?

指导妊娠伴慢性高血压女性降压药物选择的随机对照试验数据较少。2017年11月,发表在《Hypertension》的一项研究旨在比较拉贝洛尔和硝苯地平,并评价种族对疗效的影响。